文献速递胸部肿瘤

ASCL1、NEUROD1、POU2F3与YAP1定义的SCLC亚型:免疫组化与组织病理学综合表征

SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
PubMed 文献 · J Thorac Oncol · 2020-10-01

该研究对174例SCLC患者样本进行ASCL1、NEUROD1、POU2F3和YAP1免疫组化分析,发现ASCL1+/NEUROD1-占41%、双阳性占37%、NEUROD1单阳性占8%、双阴性占14%。POU2F3表达于7%的SCLC且与ASCL1/NEUROD1互斥,YAP1低表达主要见于复合型SCLC。ASCL1/NEUROD1双阴性肿瘤为神经内分泌低表达亚型,标志物表达在原生样本中较实验模型更具异质性。

要点

  • ASCL1/NEUROD1双阴性SCLC占14%,为神经内分泌低表达亚型。
  • POU2F3表达于7%的SCLC,与ASCL1和NEUROD1互斥。
  • ASCL1优势型与NEUROD1优势型均呈神经内分泌标志物高/TTF-1高/DLL3高。

核心结论

  • ASCL1/NEUROD1双阴性肿瘤构成独特的神经内分泌低表达SCLC亚型,或与POU2F3相关或缺乏已知主导调控因子。
  • 这些标志物在原生样本中的表达谱较实验模型更具异质性,尤其ASCL1/NEUROD1共表达高发。

研究设计与样本

  • 对174例SCLC患者样本进行ASCL1、NEUROD1、POU2F3和YAP1免疫组化分析。
  • 将标志物定义的亚型与组织学特征、经典神经内分泌标志物及TTF-1、DLL3表达进行关联分析。

主要发现

  • ASCL1和NEUROD1表达分布:41%为ASCL1+/NEUROD1-,37%为ASCL1+/NEUROD1+,8%为ASCL1-/NEUROD1+,14%为ASCL1-/NEUROD1-。
  • 按相对表达,69%的病例为ASCL1优势型,17%为NEUROD1优势型。
  • POU2F3表达于7%的SCLC,且与ASCL1和NEUROD1互斥。
  • YAP1低表达,主要见于复合型SCLC,且不与其它亚型互斥。
  • ASCL1优势型和NEUROD1优势型均与神经内分泌标志物高/TTF-1高/DLL3高相关,而POU2F3及其他双阴性肿瘤为神经内分泌标志物低/TTF-1低/DLL3低。

临床怎么用

  • 免疫组化可基于ASCL1、NEUROD1、POU2F3和YAP1对SCLC进行蛋白水平分型。
  • 双阴性SCLC呈神经内分泌低表达,可能影响DLL3等靶向治疗标志物的评估。

局限性

  • 研究为免疫组化表达谱分析,预后和治疗意义尚需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Recent studies have identified subtypes of small cell lung carcinoma (SCLC) defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional regulators. There are only limited data on the distribution of these markers at the protein level and associated pathologic characteristics in clinical SCLC samples. METHODS: The expression of ASCL1, NEUROD1, POU2F3, and YAP1 was analyzed by immunohistochemistry in 174 patient samples with SCLC. Subtypes defined by these markers were correlated with histologic characteristics, expression of classic neuroendocrine markers (synaptophysin, chromogranin A, CD56, INSM1), and other SCLC markers, including the neuroendocrine phenotype-associated markers TTF-1 and DLL3. RESULTS: ASCL1 and NEUROD1 expression had the following distribution: (1) 41% ASCL1+/NEUROD1-; (2) 37% ASCL1+/NEUROD1+; (3) 8% ASCL1-/NEUROD1+; and (4) 14% ASCL1-/NEUROD1-. On the basis of their relative expression, 69% of cases were ASCL1-dominant and 17% were NEUROD1-dominant. POU2F3 was expressed in 7% of SCLC and was mutually exclusive of ASCL1 and NEUROD1. YAP1 was expressed at low levels, primarily in combined SCLC, and was not exclusive of other subtypes. Both ASCL1-dominant and NEUROD1-dominant subtypes were associated with neuroendocrine markerhigh/TTF-1high/DLL3high profile, whereas POU2F3 and other ASCL1/NEUROD1 double-negative tumors were neuroendocrine markerlow/TTF-1low/DLL3low. CONCLUSIONS: This is the first comprehensive immunohistochemical and histopathologic analysis of novel SCLC subtypes in patient samples. We confirm that ASCL1/NEUROD1 double-negative tumors represent a distinct neuroendocrine-low subtype of SCLC, which is either uniquely associated with POU2F3 or lacks a known dominant regulator. The expression profiles of these markers appear more heterogeneous in native samples than in experimental models, particularly with regard to the high prevalence of ASCL1/NEUROD1 coexpression. These findings may have prognostic and therapeutic implications and warrant further clinical investigation.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Baine MK, Hsieh MS, Lai WV, et al. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. J Thorac Oncol. 2020. PMID: 33011388. doi:10.1016/j.jtho.2020.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。